Featured Insights

  1. Navigating The CGT Supply Chain: Key Logistical Challenges And Solutions 7/16/2025

    Commercializing cell and gene therapies requires overcoming complex logistical hurdles. Customized strategies for temperature control, compliance, and end-to-end delivery are crucial to prevent supply chain issues.

  2. Navigating The Complex Regulatory World Of ATMPs/CGTs 1/15/2026

    Discover how shifting definitions for ATMPs and CGTs impact global development strategies, from CMC validation requirements to navigating the latest European pharmaceutical legislation and expedited regulatory pathways.

  3. The Need For Adaptive Distribution Partners For Cell And Gene Therapies 1/6/2026

    Optimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.

  4. Overcoming Regulatory, Pharmacovigilance, And Market Access Roadblocks To European Expansion 7/7/2026

    With 30 national HTA bodies, an EU-QPPV requirement, and MFN pricing now linking European reimbursement rates to U.S. drug prices, launching in Europe demands a coordinated global strategy.

  5. A Year Of Reflection And Preparation 1/3/2025

    The Trial Master File (TMF) landscape in 2025 will require companies to stay attuned to the evolving ICH E6(R3) guidelines and the full implementation of the CTIS.